dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Sabaté Gallego, Mònica |
dc.contributor.author | Vidal Guitart, Xavier |
dc.contributor.author | Ballarin Alins, Maria Elena |
dc.contributor.author | Rottenkolber, M. |
dc.contributor.author | Schmied, S. |
dc.contributor.author | Grave, B. |
dc.contributor.author | Ibáñez, Luisa |
dc.date.accessioned | 2022-05-31T09:06:46Z |
dc.date.available | 2022-05-31T09:06:46Z |
dc.date.issued | 2021-11 |
dc.identifier.citation | Sabaté M, Vidal X, Ballarin E, Rottenkolber M, Schmiedl S, Grave B, et al. Adherence to Direct Oral Anticoagulants in Patients With Non-Valvular Atrial Fibrillation: A Cross-National Comparison in Six European Countries (2008-2015). Front Pharmacol. 2021 Nov;12:682890. |
dc.identifier.issn | 1663-9812 |
dc.identifier.uri | https://hdl.handle.net/11351/7604 |
dc.description | Anticoagulants; Europe; Non valvular atrial fibrillation |
dc.description.abstract | Aims: To describe and compare the adherence to different direct oral anticoagulants (DOACs) in eight European databases representing six countries.
Methods: Longitudinal drug utilization study of new users (≥18 years) of DOACs (dabigatran, rivaroxaban, apixaban) with a diagnosis of non-valvular atrial fibrillation (2008–2015). Adherence was examined by estimating persistence, switching, and discontinuation rates at 12 months. Primary non-adherence was estimated in BIFAP and SIDIAP databases.
Results: The highest persistence rate was seen for apixaban in the CPRD database (81%) and the lowest for dabigatran in the Mondriaan database (22%). The switching rate for all DOACs ranged from 2.4 to 13.1% (Mondriaan and EGB databases, respectively). Dabigatran had the highest switching rate from 5.0 to 20.0% (Mondriaan and EGB databases, respectively). The discontinuation rate for all DOACs ranged from 16.0 to 63.9% (CPRD and Bavarian CD databases, respectively). Dabigatran had the highest rate of discontinuers, except in the Bavarian CD and AOK NORDWEST databases, ranging from 23.2 to 64.6% (CPRD and Mondriaan databases, respectively). Combined primary non-adherence for examined DOACs was 11.1% in BIFAP and 14.0% in SIDIAP. There were differences in population coverage and in the type of drug data source among the databases.
Conclusion: Despite the differences in the characteristics of the databases and in demographic and baseline characteristics of the included population that could explain some of the observed discrepancies, we can observe a similar pattern throughout the databases. Apixaban was the DOAC with the highest persistence. Dabigatran had the highest proportion of discontinuers and switchers at 12 months in most databases (EMA/2015/27/PH). |
dc.language.iso | eng |
dc.publisher | Frontiers Media |
dc.relation.ispartofseries | Frontiers in Pharmacology;12 |
dc.rights | Attribution 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ |
dc.source | Scientia |
dc.subject | Medicació oral |
dc.subject | Fibril·lació auricular - Tractament |
dc.subject | Medicaments - Ús |
dc.subject.mesh | Atrial Fibrillation |
dc.subject.mesh | /drug therapy |
dc.subject.mesh | Drug Utilization |
dc.subject.mesh | Administration, Oral |
dc.title | Adherence to Direct Oral Anticoagulants in Patients With Non-Valvular Atrial Fibrillation: A Cross-National Comparison in Six European Countries (2008–2015) |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.3389/fphar.2021.682890 |
dc.subject.decs | fibrilación atrial |
dc.subject.decs | /farmacoterapia |
dc.subject.decs | utilización de medicamentos |
dc.subject.decs | administración oral |
dc.relation.publishversion | https://doi.org/10.3389/fphar.2021.682890 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Sabaté M, Vidal X, Ibáñez L] Fundació Institut Català de Farmacologia (FICF), Barcelona, Spain. Servei de Farmacologia Clínica, Vall d'Hebron Hospital Universitari, Barcelona, Spain. Departament de Farmacologia, Toxicologia i Terapèutica, Universitat Autònoma de Barcelona, Bellaterra, Spain. [Ballarin E] Fundació Institut Català de Farmacologia (FICF), Barcelona, Spain. Servei de Farmacologia Clínica, Vall d'Hebron Hospital Universitari, Barcelona, Spain. [Rottenkolber M] Diabetes Research Group, Medizinische Klinik und Poliklinik IV, Klinikum der Universität München, Munich, Germany. [Schmiedl S] Department of Clinical Pharmacology, School of Medicine, Faculty of Health, Witten/Herdecke University, Witten, Germany. Philipp Klee-Institute for Clinical Pharmacology, Helios University Hospital Wuppertal, Wuppertal, Germany. [Grave B] AOK NORDWEST, Dortmund, Germany |
dc.identifier.pmid | 34803665 |
dc.identifier.wos | 000720117800001 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |